Home/Filings/4/0001213900-25-014306
4//SEC Filing

Xu Jiandong 4

Accession 0001213900-25-014306

CIK 0001844417other

Filed

Feb 13, 7:00 PM ET

Accepted

Feb 14, 4:30 PM ET

Size

9.0 KB

Accession

0001213900-25-014306

Insider Transaction Report

Form 4
Period: 2024-10-30
Xu Jiandong
Chief Financial Officer
Transactions
  • Award

    Nonstatutory Share Option

    2024-10-30+509,204509,203 total
    Exercise: $0.81From: 2024-10-31Exp: 2034-10-29Common Stock (509,204 underlying)
  • Award

    Incentive Share Option

    2024-10-30+490,796490,796 total
    Exercise: $0.81From: 2024-10-31Exp: 2034-10-29Common Stock (490,796 underlying)
Footnotes (4)
  • [F1]On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Jiangdong "Peter" Xu an incentive share option grant of 490,796 shares.
  • [F2]The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months. Each subsequent monthly vesting will represent a total of 1/48 of the total award, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.
  • [F3]On October 31, 2024, the Board of the Company awarded Mr. Xu a nonstatutory shares option grant of 509,204 shares.
  • [F4]The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024.

Documents

1 file

Issuer

Estrella Immunopharma, Inc.

CIK 0001844417

Entity typeother

Related Parties

1
  • filerCIK 0001920399

Filing Metadata

Form type
4
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:30 PM ET
Size
9.0 KB